Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs

Recordati CEO Robert Koremans expects the 15% U.S. tariff on imported European pharmaceuticals to exempt rare disease drugs, a critical segment that generated €515.7 million in H1 2025 revenues for the Italian group. Koremans anticipates this special treatment for rare diseases will make the overall tariff impact on Recordati's financial results manageable, suggesting a potential carve-out for high-need therapeutic areas within broader trade disputes.

Analysis

Recordati (RECI.MI) is confronting a significant external risk from a proposed 15% U.S. tariff on imported European pharmaceuticals. However, company management has provided guidance that mitigates the perceived impact, based on the composition of its product portfolio. CEO Robert Koremans expressed confidence that Recordati's treatments for rare diseases, a business segment that generated a substantial €515.7 million in revenue in the first half of 2025, will be exempted from the new tariffs. This expectation of a "special, better treatment" for rare disease drugs underpins the CEO's assessment that the overall financial impact on the company will be "manageable." The situation highlights how a company's strategic focus on a specialized therapeutic area can potentially insulate it from broader geopolitical trade disputes, though its performance outlook remains contingent on this specific regulatory carve-out being officially confirmed.

Key Decisions for Investors

• Investors should closely monitor official U.S. trade policy announcements for confirmation of the tariff exemption for rare disease drugs, as Recordati's 'manageable' impact guidance is entirely contingent on this carve-out.
• The company's significant reliance on its rare disease franchise should be viewed as both a potential defensive moat against tariffs and a key concentration risk if the exemption fails to materialize.
• While the CEO's optimistic guidance may support a hold position, any official indication that rare disease treatments will be included in the tariffs would serve as a significant bearish catalyst, warranting an immediate reassessment of the company's valuation.